Marielle Fares, PharmD, BCGP

Oncoloytic viruses are an emerging class of cancer therapeutics that may provide a new strategy against malignant tumors.

Research on combination therapies involving human papillomavirus-targeted vaccines and immunotherapies continues to expand in phase 2 and 3 trials in patients with head and neck squamous cell carcinoma.